EHA in 5 Minutes | Professor Huanling Zhu: PONAZA Trial— Ponatinib and Azacitidine for Treating Myeloid Blast Crisis in CML (NCT03895671)

EHA in 5 Minutes | Professor Huanling Zhu: PONAZA Trial— Ponatinib and Azacitidine for Treating Myeloid Blast Crisis in CML (NCT03895671)

2024.06.26
The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13-16, 2024, in Madrid, Spain. As the largest international event in the field of hematology in Europe, this conference attracts numerous renowned experts and scholars from around the world to share and discuss innovative concepts, the latest scientific research, and clinical study results in hematology. To gain a deeper understanding of the latest research in Chronic Myeloid Leukemia (CML), "Oncology Frontier - Hematology Frontier" has invited Professor Huanling Zhu from West China Hospital of Sichuan University, to provide an in-depth interpretation.
Chinese CAR-T Cell Therapy Phase 1 Study Shows Promise for HIV Functional Cure

Chinese CAR-T Cell Therapy Phase 1 Study Shows Promise for HIV Functional Cure

2024.06.25
In a pioneering clinical trial, a novel multifunctional CAR-T cell treatment has demonstrated remarkable efficacy and safety in HIV-1 infected patients, potentially paving the way for a functional cure for HIV/AIDS. Published in Cell Discovery, the phase I study introduced M10 CAR-T cells, engineered to incorporate endogenous broadly neutralizing antibodies (bNAbs) and the follicle-homing receptor CXCR5.
WHO Reports on Rising HIV Drug Resistance Amid Integrase Inhibitor Use

WHO Reports on Rising HIV Drug Resistance Amid Integrase Inhibitor Use

2024.06.25
The World Health Organization (WHO) has released a concise report highlighting a concerning trend in HIV drug resistance (HIVDR) in the integrase strand transfer inhibitors (INSTI) era. The report notes the high efficacy of dolutegravir (DTG)-based antiretroviral therapy (ART) in suppressing viral loads, exceeding 90%. However, it warns that HIVDR to DTG is emerging at higher rates than clinical trials predicted, with resistance levels ranging from 3.9% to 19.6% among surveyed populations.
EASL Five Minutes丨Professor Huiying Rao: Advances in the Application of Non-invasive Diagnostic Prediction Models in the Field of Metabolic-Associated Fatty Liver Disease

EASL Five Minutes丨Professor Huiying Rao: Advances in the Application of Non-invasive Diagnostic Prediction Models in the Field of Metabolic-Associated Fatty Liver Disease

2024.06.25
The recently concluded 2024 European Association for the Study of the Liver (EASL) Annual Meeting provided a platform for hepatology experts and scholars from around the world to exchange and collaborate. This year's meeting brought together top liver disease experts from across the globe to discuss cutting-edge issues and the latest research advances in hepatology. Among the various topics, research on fatty liver disease was particularly noteworthy, not only for its relevance to the health and well-being of a large number of patients but also for its significance in the development of hepatology treatments. To keep our readers updated on the highlights of the conference, the editorial board of "Hepatology Digest" invited Professor Huiying Rao from Peking University People's Hospital to share insights on non-invasive diagnosis and assessment in the field of Metabolic-Associated Fatty Liver Disease (MAFLD), presenting the latest and most authoritative academic information to our readers.
National Rise and All-Human BCMA-Targeted CAR-T Therapy Brings New Hope for Relapsed/Refractory Multiple Myeloma Treatment

National Rise and All-Human BCMA-Targeted CAR-T Therapy Brings New Hope for Relapsed/Refractory Multiple Myeloma Treatment

2024.06.24
The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13 to 16, 2024, in Madrid, Spain. This conference, the largest international event in the field of hematology in Europe, attracts numerous renowned experts and scholars each year to share and discuss innovative ideas, the latest scientific research, and clinical findings in hematology. At this year's conference, the research team led by Professor Wenming Chen from Beijing Chao-Yang Hospital , Capital Medical University presented their findings in an oral presentation (S209) on the Phase II study of all-human BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma (RRMM). To gain deeper insights into the latest research in the RRMM field, Oncology Frontier - Hematology Frontier invited Professor Wenming Chen for an in-depth discussion.
Construction for Prostate Cancer Patients with a History of Malignancy by Professor Kan Gong ‘s Team | AUA 2024

Construction for Prostate Cancer Patients with a History of Malignancy by Professor Kan Gong ‘s Team | AUA 2024

2024.06.24
With advancements in cancer screening, diagnosis, and treatment, the survival period of cancer patients has significantly increased. Long-term management of cancer patients should not only focus on the primary tumor but also monitor for the occurrence of secondary primary tumors (SPTs) and multiple primary tumors through regular check-ups and screenings. Secondary primary tumors are defined as new independent malignant tumors that arise in different locations following treatment for an initial malignancy, and they are not recurrences or metastases of the first primary tumor. Various factors may contribute to the development of SPTs, such as age, obesity, genetic susceptibility, the stage at diagnosis of the first primary tumor, and environmental exposure. Previous studies have shown that the incidence of SPTs in cancer patients ranges from 8-16%, varying by tumor site . SPTs pose a significant threat to cancer patients' survival, accounting for 55% of cancer-related deaths .
EHA Roundtable | Professor Xiaohui Zhang’s Team Wins YoungEHA Best Abstract Award: Comprehensive Analysis of Outstanding Research Results

EHA Roundtable | Professor Xiaohui Zhang’s Team Wins YoungEHA Best Abstract Award: Comprehensive Analysis of Outstanding Research Results

2024.06.24
The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held from June 13-16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world each year to share and discuss innovative concepts and the latest scientific and clinical research results in hematology. At this year's conference, Professor Xiaohui Zhang's team from Peking University People's Hospital performed outstandingly, with four studies selected for oral presentation, and one study awarded the YoungEHA Best Abstract Award, making it one of the four global award-winning studies of the year and the only one from China to receive this honor. This achievement not only highlights the team's exceptional strength but also showcases the potential and capabilities of Chinese researchers. "Oncology Frontier - Hematology Frontier" specially invited Professor Xiaohui Zhang and his team members for a roundtable discussion to share their research findings, covering non-invasive diagnostic techniques, mechanisms of CAR-T cell therapy toxicity in relapsed/refractory T-cell leukemia, prognosis models for mixed phenotype acute leukemia (MPAL), and innovative clinical research in immune thrombocytopenia (ITP).
EHA Expert Interview | Professor Jun Ma: China’s Innovative Contributions Draw Global Attention, Major Breakthroughs in AML

EHA Expert Interview | Professor Jun Ma: China’s Innovative Contributions Draw Global Attention, Major Breakthroughs in AML

2024.06.24
The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held from June 13-16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world each year to share and discuss innovative concepts and the latest scientific and clinical research results in hematology. At this year's conference, Professor Jun Ma's team from the Harbin Institute of Hematology and Oncology presented real-world study results on the treatment of acute myeloid leukemia (AML) with mitoxantrone liposome. "Oncology Frontier - Hematology Frontier" invited Professor Jun Ma for an interview to interpret the study content, discuss field development trends, and introduce the outstanding performance of Chinese teams at this conference.